Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 20628053 
Sen A, et al. (2010) Paxillin regulates androgen- and epidermal growth factor-induced MAPK signaling and cell proliferation in prostate cancer cells. J Biol Chem 285, 28787-95 20628053
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

Y869-p - EGFR (human)
Orthologous residues
EGFR (human): Y869‑p, EGFR iso5 (human): Y869‑p, EGFR (mouse): Y871‑p, EGFR (rat): Y870‑p, EGFR (pig): Y869‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  prostate cancer
 Relevant cell lines - cell types - tissues:  A431 (epithelial), LNCaP (prostate cell), PC3 (prostate cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DHT increase
galardin DHT inhibit treatment-induced increase
AG1478 DHT inhibit treatment-induced increase
PP2 DHT no effect upon treatment-induced increase

T202-p - ERK1 (human)
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  prostate cancer
 Relevant cell lines - cell types - tissues:  LNCaP (prostate cell), PC3 (prostate cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DHT increase
DHT PXN iso2 (human) increase PXN siRNA inhibits increase
hydroxyflutamide DHT inhibit treatment-induced increase
AG1478 DHT inhibit treatment-induced increase
erlotinib DHT inhibit treatment-induced increase
PP2 DHT inhibit treatment-induced increase
galardin DHT inhibit treatment-induced increase
U0126 DHT inhibit treatment-induced increase
EGF increase
EGF PXN iso2 (human) increase PXN siRNA inhibits induction
phorbol ester increase
siRNA phorbol ester no effect upon treatment-induced increase

Y204-p - ERK1 (human)
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  prostate cancer
 Relevant cell lines - cell types - tissues:  LNCaP (prostate cell), PC3 (prostate cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DHT increase
DHT PXN iso2 (human) increase PXN siRNA inhibits increase
hydroxyflutamide DHT inhibit treatment-induced increase
AG1478 DHT inhibit treatment-induced increase
erlotinib DHT inhibit treatment-induced increase
PP2 DHT inhibit treatment-induced increase
galardin DHT inhibit treatment-induced increase
U0126 DHT inhibit treatment-induced increase
EGF increase
EGF PXN iso2 (human) increase PXN siRNA inhibits induction
phorbol ester increase
siRNA phorbol ester no effect upon treatment-induced increase

T185-p - ERK2 (human)
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  prostate cancer
 Relevant cell lines - cell types - tissues:  LNCaP (prostate cell), PC3 (prostate cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DHT increase
DHT PXN iso2 (human) increase PXN siRNA inhibits increase
hydroxyflutamide DHT inhibit treatment-induced increase
AG1478 DHT inhibit treatment-induced increase
erlotinib DHT inhibit treatment-induced increase
PP2 DHT inhibit treatment-induced increase
galardin DHT inhibit treatment-induced increase
U0126 DHT inhibit treatment-induced increase
EGF increase
EGF PXN iso2 (human) increase PXN siRNA inhibits induction
phorbol ester increase
siRNA phorbol ester no effect upon treatment-induced increase

Y187-p - ERK2 (human)
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  prostate cancer
 Relevant cell lines - cell types - tissues:  LNCaP (prostate cell), PC3 (prostate cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DHT increase
DHT PXN iso2 (human) increase PXN siRNA inhibits increase
hydroxyflutamide DHT inhibit treatment-induced increase
AG1478 DHT inhibit treatment-induced increase
erlotinib DHT inhibit treatment-induced increase
PP2 DHT inhibit treatment-induced increase
galardin DHT inhibit treatment-induced increase
U0126 DHT inhibit treatment-induced increase
EGF increase
EGF PXN iso2 (human) increase PXN siRNA inhibits induction
phorbol ester increase
siRNA phorbol ester no effect upon treatment-induced increase

S218-p - MEK1 (human)
Orthologous residues
MEK1 (human): S218‑p, MEK1 (mouse): S218‑p, MEK1 (rat): S218‑p, MEK1 (rabbit): S218‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  prostate cancer
 Relevant cell lines - cell types - tissues:  LNCaP (prostate cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DHT PXN iso2 (human) increase PXN siRNA inhibits increase
EGF PXN iso2 (human) increase PXN siRNA inhibits increase

S222-p - MEK1 (human)
Orthologous residues
MEK1 (human): S222‑p, MEK1 (mouse): S222‑p, MEK1 (rat): S222‑p, MEK1 (rabbit): S222‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  prostate cancer
 Relevant cell lines - cell types - tissues:  LNCaP (prostate cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DHT PXN iso2 (human) increase PXN siRNA inhibits increase
EGF PXN iso2 (human) increase PXN siRNA inhibits increase

S222-p - MEK2 (human)
Orthologous residues
MEK2 (human): S222‑p, MEK2 (mouse): S222‑p, MEK2 (rat): S222‑p, MEK2 (chicken): S220‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  prostate cancer
 Relevant cell lines - cell types - tissues:  LNCaP (prostate cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DHT PXN iso2 (human) increase PXN siRNA inhibits increase
EGF PXN iso2 (human) increase PXN siRNA inhibits increase

S226-p - MEK2 (human)
Orthologous residues
MEK2 (human): S226‑p, MEK2 (mouse): S226‑p, MEK2 (rat): S226‑p, MEK2 (chicken): S224‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  prostate cancer
 Relevant cell lines - cell types - tissues:  LNCaP (prostate cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DHT PXN iso2 (human) increase PXN siRNA inhibits increase
EGF PXN iso2 (human) increase PXN siRNA inhibits increase

Y31-p - PXN iso2 (human)
Orthologous residues
PXN (human): Y31‑p, PXN iso2 (human): Y31‑p, PXN iso3 (human): Y31‑p, PXN iso6 (human): Y38‑p, PXN (mouse): Y31‑p, PXN iso2 (mouse): Y31‑p, PXN (rat): Y31‑p, PXN (chicken): Y31‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  prostate cancer
 Relevant cell lines - cell types - tissues:  LNCaP (prostate cell), PC3 (prostate cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DHT increase
AG1478 DHT inhibit treatment-induced increase
PP2 DHT inhibit treatment-induced increase
U0126 DHT no effect upon treatment-induced increase
Downstream Regulation
 Effect of modification (function):  phosphorylation
 Effect of modification (process):  cell cycle regulation
 Comments:  essential for EGFR-mediated Erk1/2 activation and cell proliferation

S83-p - PXN iso2 (human)
Orthologous residues
PXN (human): S83‑p, PXN iso2 (human): S83‑p, PXN iso3 (human): S83‑p, PXN iso6 (human): S90‑p, PXN (mouse): S83‑p, PXN iso2 (mouse): S83‑p, PXN (rat): S83‑p, PXN (chicken): S83‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  prostate cancer
 Relevant cell lines - cell types - tissues:  LNCaP (prostate cell), PC3 (prostate cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme
KINASE ERK2 (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DHT increase
AG1478 DHT inhibit treatment-induced increase
PP2 DHT inhibit treatment-induced increase
U0126 DHT inhibit treatment-induced increase
phorbol ester increase
U0126 phorbol ester inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (process):  carcinogenesis, altered, cell cycle regulation, transcription, altered
 Comments:  regulates Erk1/2-induced cell proliferation and transcription

Y118-p - PXN iso2 (human)
Orthologous residues
PXN (human): Y118‑p, PXN iso2 (human): Y118‑p, PXN iso3 (human): Y118‑p, PXN iso6 (human): Y125‑p, PXN (mouse): Y118‑p, PXN iso2 (mouse): Y118‑p, PXN (rat): Y118‑p, PXN (chicken): Y118‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  prostate cancer
 Relevant cell lines - cell types - tissues:  LNCaP (prostate cell), PC3 (prostate cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DHT increase
AG1478 DHT inhibit treatment-induced increase
PP2 DHT inhibit treatment-induced increase
U0126 DHT no effect upon treatment-induced increase
Downstream Regulation
 Effect of modification (function):  phosphorylation
 Effect of modification (process):  cell cycle regulation
 Comments:  essential for EGFR-mediated Erk1/2 activation and cell proliferation

S126-p - PXN iso2 (human)
Orthologous residues
PXN (human): S126‑p, PXN iso2 (human): S126‑p, PXN iso3 (human): S126‑p, PXN iso6 (human): S133‑p, PXN (mouse): S126‑p, PXN iso2 (mouse): S126‑p, PXN (rat): S126‑p, PXN (chicken): S126‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  prostate cancer
 Relevant cell lines - cell types - tissues:  LNCaP (prostate cell), PC3 (prostate cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme
KINASE ERK2 (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DHT increase
AG1478 DHT inhibit treatment-induced increase
PP2 DHT inhibit treatment-induced increase
U0126 DHT inhibit treatment-induced increase
phorbol ester increase
U0126 phorbol ester inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (process):  carcinogenesis, altered, cell cycle regulation, transcription, altered
 Comments:  regulates Erk1/2-induced cell proliferation and transcription

S130-p - PXN iso2 (human)
Orthologous residues
PXN (human): S130‑p, PXN iso2 (human): S130‑p, PXN iso3 (human): S130‑p, PXN iso6 (human): S137‑p, PXN (mouse): S130‑p, PXN iso2 (mouse): S130‑p, PXN (rat): S130‑p, PXN (chicken): S130‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Disease tissue studied:  prostate cancer
 Relevant cell lines - cell types - tissues:  LNCaP (prostate cell), PC3 (prostate cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK1 (human) pharmacological inhibitor of upstream enzyme
KINASE ERK2 (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
U0126 phorbol ester inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (process):  carcinogenesis, altered, cell cycle regulation, transcription, altered
 Comments:  regulates Erk1/2-induced cell proliferation and transcription

Y419-p - Src (human)
Orthologous residues
Src (human): Y419‑p, Src (mouse): Y424‑p, Src iso2 (mouse): Y418‑p, Src (rat): Y419‑p, Src (chicken): Y416‑p
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DHT increase
AG1478 inhibit treatment-induced increase
PP2 DHT inhibit treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.